Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 22Other hematologic neoplasm 13Gastrointestinal 9Lymphoid 8Genitourinary 6Tumor-Agnostic 5Other solid neoplasm 5Head & Neck 5Gynecologic 5CNS 5Thoracic 4Plasma cell 4Dermatologic 4Sarcoma 3Other 2Myeloid 2Classical hematology 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Carcinoma 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Blood Specimen Collection 28Radiosurgery 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Tablets × Tumor-Agnostic × Clear all
NCT04393454 2024-07-25

Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

Albert Einstein College of Medicine

Phase 2 Terminated
6 enrolled 12 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01173913 2019-01-10

Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir

The Netherlands Cancer Institute

Phase 1 Completed
57 enrolled
Tumor-Agnostic

Neoplasms

NCT02536391 2016-11-02

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Genentech, Inc.

Phase 1 Completed
18 enrolled
Tumor-Agnostic

Neoplasms

NCT00941863 2016-03-22

Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Bayer

Phase 1 Completed
158 enrolled 17 charts
Tumor-Agnostic

Carcinoma

NCT00667485 2014-01-17

Rapamycin Plus Bevacizumab in Advanced Cancers

University of Chicago

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡